Logo

Inivata and Collaborators Report Results of RaDaR MRD Test in (CHiRP) Study for the Treatment of Breast Cancer

Share this
Inivata and Collaborators Report Results of RaDaR MRD Test in (CHiRP) Study for the Treatment of Breast Cancer

Inivata and Collaborators Report Results of RaDaR MRD Test in (CHiRP) Study for the Treatment of Breast Cancer

Shots:

  • The (CHiRP) study evaluates RaDaR personalized MRD assay in patients with high-risk, early-stage HR+ HER2- breast cancer. The study was supported by AstraZeneca & conducted in conjunction with the Dana-Farber Cancer Institute
  • The 83-patient cohort's ctDNA in blood samples were examined using RaDaR assay through patient-specific primer panels with a median follow-up was 2yrs. from 1st blood sample, 10% of patients had MRD+ results, published in the Journal of Clinical Oncology & presented at ASCO 2022
  • 6 patients (7.2%) developed distant metastatic recurrence & ctDNA was identified with an m-ctDNA lead time of 12.4mos, 2 MRD+ patients had not experienced clinical recurrence. These findings confirm the RaDaR assay's clinical relevance to enhance patient outcomes

Ref: GlobalNewswire | Image: Inivata

Click here to­ read the full press release 

Neha

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions